GlassScriptPhysician profile
Edgar M Cespedes
NPI 1356304455
$66,515.70
in general payments reported to CMS, 2019-2025
25 companies · $334 in 2025
The $334 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $8,918 · 2021: $12K · 2022: $960 · 2023: $773 · 2024: $786 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,875 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,875.36 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $36,050.64 | 2019-2022 | |
| Esperion Therapeutics, INC. | $14,224.06 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $10,999.03 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $1,728.21 | 2019-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $848.44 | 2019 | |
| Novo Nordisk INC | $455.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $377.68 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Impulse Dynamics (USA) INC. | $260.51 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $211.79 | 2023-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $208.04 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.71 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $171.65 | 2019-2025 | Camzyos |
| Agepha Pharma Fz LLC | $171.49 | 2024 | Lodoco |
| Kowa Pharmaceuticals America, INC. | $121.92 | 2019-2021 | |
| Amgen INC. | $94.85 | 2020-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $71.59 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $61.28 | 2019 | |
| Lilly USA, LLC | $55.09 | 2023-2024 | Mounjaro |
| Baxter Healthcare | $51.10 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| Edwards Lifesciences Corporation | $49.69 | 2024 | |
| Corcept Therapeutics | $24.48 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $23.59 | 2025 | |
| Exact Sciences Corporation | $22.08 | 2025 | The Cologuard Plus Collection Kit |
| Abbott Laboratories | $20.73 | 2023 | Freestyle Libre 2 |
| Vifor Pharma, INC. | $17.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Cespedes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.